Simplification of Imipenem Dosing by Removal of Weight-Based Adjustments

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Pharmacokinetics

Background:

• Imipenem dosing for renal insufficiency traditionally included adjustments for creatinine clearance and body weight.
• Previous dosing regimens may not have optimally balanced efficacy and safety across all patient weight categories.

Purpose of the Study:

• To re-evaluate imipenem pharmacokinetics in patients with renal insufficiency.
• To develop revised dosing recommendations by assessing the influence of creatinine clearance and body weight.
• To simplify imipenem dosing while ensuring therapeutic efficacy and patient safety.

Main Methods:

• A population pharmacokinetic model was constructed using data from 465 patients and 3300 pharmacokinetic samples.
• Simulations were performed to evaluate the impact of revised dosing strategies on target attainment.
• Data analysis informed updates to the imipenem labeling in the US and Europe.

Main Results:

• Revised dosing recommendations were developed, removing the need for body weight-adjusted dosing.
• The optimized regimen demonstrated improved probability of target attainment (>90%) at key minimum inhibitory concentration breakpoints (1 and 2 μg/mL), especially for low-body-weight patients.
• Previously, low-body-weight patients had <90% probability of target attainment.

Conclusions:

• Additional dose adjustments for body weight are not necessary for imipenem in patients with renal insufficiency.
• The new dosing scheme simplifies administration and maintains patient safety and efficacy.
• Updated labeling in the US and Europe reflects these revised, optimized dosing recommendations.